Rik J. Deitsch - 15 Nov 2021 Form 5 Insider Report for NUTRA PHARMA CORP

Reporting relationship: President, CEO, Director
Issuer ticker: N/A
Reported as of: 15 Nov 2021
Net transaction value: $0
SEC form: 5
Accepted by SEC: 14 Jan 2022, 16:16:41 UTC
Source filing: View source filing
Reporting owner signature: /s/ Rik J. Deitsch

Key filing fact

Rik J. Deitsch filed Form 5 for NUTRA PHARMA CORP on 14 Jan 2022.

Key facts

This page summarizes Rik J. Deitsch's Form 5 filing for NUTRA PHARMA CORP.
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Jan 2022, 16:16.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NPHC transaction

Series B Preferred Stock

Purchase

Transaction value
Shares: +3,000,000
Change %
Price
Shares after: 3,000,000
Date: 15 Nov 2021
Ownership: Direct
Footnotes: F1, F2

NPHC transaction

Series B Preferred Stock

Purchase

Transaction value
Shares: +9,000,000
Change %: +300%
Price
Shares after: 12,000,000
Date: 15 Nov 2021
Ownership: Direct
Footnotes: F1, F3

NPHC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 43,298,859
Date: 15 Nov 2021
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Series B preferred stock have no right of conversion to shares of common stock. Each share of Series B preferred stock is entitled to vote with the Corporation's common stock as a single class on all matters submitted to common stock holders to vote. Each share of Series B Preferred Stock is entitled to one thousand votes per share.

Footnote F2

3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch were exchanged for an equal number of Series B Preferred Stock of the Company pursuant to a share exchange agreement between Rik Deitsch and the Company.

Footnote F3

9,000,000 shares of Series B Preferred Stock were issued in satisfaction of corporate debt owed by the Company to Mr. Deitsch pursuant to a resolution adopted by the board of directors of the Company.